Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13965218 | 0.92 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1GAAMEN1KMT2A | |
| SCHEMBL14625112 | 0.86 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1GAAMEN1KMT2A | |
| SCHEMBL4101815 | 0.85 | MEN1 (0.58) | ALDH1A1L3MBTL1GAAMEN1KMT2A | |
| SCHEMBL4114816 | 0.79 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1GAAMEN1KMT2A | |
| SCHEMBL13940505 | 0.79 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1GAAMEN1KMT2A | |
| SCHEMBL4101837 | 0.79 | ALDH1A1 (0.40) | ALDH1A1L3MBTL1GAAMEN1KMT2A | |
| SCHEMBL4114917 | 0.78 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1GAAMEN1KMT2A | |
| SCHEMBL4100184 | 0.77 | KMT2A (0.46) | ALDH1A1L3MBTL1GAAMEN1KMT2A | |
| SCHEMBL4100554 | 0.77 | KMT2A (0.56) | ALDH1A1L3MBTL1GAAMEN1KMT2A | |
| SCHEMBL31261702 | 0.75 | SGMS2 (0.72) | SGMS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012127-A1 | Thiophene-2-Carboxamide Derivatives as Alpha 7 Nicotinic Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | claimed |
| EP-1910328-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS ALPHA 7 NICOTINIC RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | claimed |
| WO-2007001225-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS ALPHA 7 NICOTINIC RECEPTOR MODULATORS. | ASTRAZENECA (SE) | 2007-01-04 | — | — | WO | claimed |
| US-20090012127-A1 | Thiophene-2-Carboxamide Derivatives as Alpha 7 Nicotinic Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| US-20090012127-A1 | Thiophene-2-Carboxamide Derivatives as Alpha 7 Nicotinic Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| EP-1910328-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS ALPHA 7 NICOTINIC RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007001225-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS ALPHA 7 NICOTINIC RECEPTOR MODULATORS. | ASTRAZENECA (SE) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012127-A1 | Thiophene-2-Carboxamide Derivatives as Alpha 7 Nicotinic Receptor Modulators | CHRNA7, CHRNA1, CHRNA5 | ALDH1A1 505/4885L3MBTL1 4508/4885GAA 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.